Carnegie Capital Asset Management buys $8,642,850 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Carnegie Capital Asset Management scooped up 1,740 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 13, 2016. The investment management firm now holds a total of 78,443 shares of Johnson & Johnson which is valued at $8,642,850.Johnson & Johnson makes up approximately 1.31% of Carnegie Capital Asset Management’s portfolio.

Johnson & Johnson opened for trading at $110 and hit $111.1 on the upside on Monday, eventually ending the session at $110.93, with a gain of 0.68% or 0.75 points. The heightened volatility saw the trading volume jump to 77,72,549 shares. Company has a market cap of $306,096 M.

Other Hedge Funds, Including , First United Bank Trust boosted its stake in JNJ in the latest quarter, The investment management firm added 436 additional shares and now holds a total of 19,716 shares of Johnson & Johnson which is valued at $2,172,309. Johnson & Johnson makes up approx 1.98% of First United Bank Trust’s portfolio.Proficio Capital Partners boosted its stake in JNJ in the latest quarter, The investment management firm added 6,199 additional shares and now holds a total of 6,650 shares of Johnson & Johnson which is valued at $724,651. Johnson & Johnson makes up approx 0.61% of Proficio Capital Partners’s portfolio.Creative Planning boosted its stake in JNJ in the latest quarter, The investment management firm added 3,723 additional shares and now holds a total of 279,960 shares of Johnson & Johnson which is valued at $30,507,241. Johnson & Johnson makes up approx 0.24% of Creative Planning’s portfolio.Toth Financial Advisory Corp reduced its stake in JNJ by selling 2,078 shares or 3.52% in the most recent quarter. The Hedge Fund company now holds 56,913 shares of JNJ which is valued at $6,201,810. Johnson & Johnson makes up approx 2.04% of Toth Financial Advisory Corp’s portfolio.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.